Clinical Trial Update: Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients [NA]

View source ↗

Summary

A completed clinical trial update describes using DX600 labeled for PET imaging to target ACE2 in patients with solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• DX600 PET imaging agent (DX600)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Solid Tumor | NA | Status: COMPLETED